Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH 03756-0001, USA.
Chest. 2010 Jun;137(6):1354-61. doi: 10.1378/chest.09-2470. Epub 2009 Dec 29.
Walking is a familiar daily activity that is generally limited by breathlessness, whereas cycling is an uncommon physical effort typically limited by leg discomfort. The hypothesis was that patients with COPD would exhibit greater improvements in exercise endurance and relief of breathlessness with bronchodilator therapy during treadmill walking compared with cycling.
In this randomized, 2 x 2, double-blind, placebo-controlled, crossover trial, 20 patients with COPD (age, 64 +/- 7 years; FEV(1), 56 +/- 14% predicted) performed constant-load endurance exercise on the treadmill and cycle ergometer at 85% of capacity after inhaling normal saline (NS) or arformoterol (ARF) (15 microg).
Increases in endurance times and consistency of responses were greater with treadmill walking (Delta: 157 +/- 286 s; P = .024; 80% improved) than with cycle exercise (Delta: 110 +/- 219 s; P = .038; 65% improved) with ARF compared with NS. However, these changes were not significantly different. The slope of breathlessness-time (mean Delta = -29%; P = .007) and the magnitude of oxygen desaturation were significantly lower with ARF compared with NS during treadmill, but not cycle, exercise. Inspiratory capacity values were similar between modes of exercise when comparing the same study medication.
Improved endurance times support both constant-load treadmill and cycle exercise to assess the efficacy of bronchodilator therapy in patients with COPD. Unique differences in physiologic and perceptual responses with bronchodilation demonstrate advantages of treadmill walking as an exercise stimulus.
clinicaltrials.gov; Identifier: NCT00754546.
行走是一种常见的日常活动,通常会受到呼吸困难的限制;而骑行则是一种不常见的体力活动,通常会受到腿部不适的限制。假设在跑步机上行走时,与骑行相比,接受支气管扩张剂治疗的 COPD 患者在运动耐力和缓解呼吸困难方面会有更大的改善。
在这项随机、2 x 2、双盲、安慰剂对照、交叉试验中,20 名 COPD 患者(年龄 64 +/- 7 岁;FEV(1),56 +/- 14%预测值)在吸入生理盐水(NS)或阿福莫特罗(ARF)(15 微克)后,在跑步机和功率自行车上以 85%的能力进行恒负荷耐力运动。
与 NS 相比,ARF 可使跑步机行走时的耐力时间和反应一致性增加(Delta:157 +/- 286 s;P =.024;80%改善),而不是骑行(Delta:110 +/- 219 s;P =.038;65%改善)。然而,这些变化没有显著差异。与 NS 相比,ARF 时跑步机运动时呼吸困难时间的斜率(平均 Delta = -29%;P =.007)和氧饱和度下降幅度显著降低,但在骑行时则不然。在比较相同的研究药物时,两种运动方式的吸气量值相似。
耐力时间的改善支持恒负荷跑步机和自行车运动来评估支气管扩张剂治疗 COPD 患者的疗效。支气管扩张剂治疗时的生理和感知反应的独特差异表明跑步机行走作为运动刺激的优势。
clinicaltrials.gov;标识符:NCT00754546。